الفهرس 
? Hepatocellular CarcinomaOnly 14 pages are availabe for public view
 |  | from | 215 |  |  |
| | | from | 215 | | |
Abstract
Introduction: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which cause approximately 600,000 to 1,000,000 deaths annually. Current determination of survival and prognosis in patients treated with TACE or TAE for unresectable HCC is mainly based on clinical assessment. Serum alpha-fetoprotein (AFP) as a well accepted tumor marker is only expressed by 60% of our patients.
Aim of the Work: To assess the clinical usefulness of pre-treatment P-VEGF level as a predictor of outcome in patients undergoing TACE therapy for HCC. To assess the value of P-VEGF as an indicator of recurrence or residual of tumor after TACE. To assess the value of P-VEGF as a marker for HCC.
Patients and Methods: The present study was carried out in Tropical Medicine Department, HCC outpatient clinic and Ain Shams University Hospitals after approval from the ethical committee of the local institute. The study was a prospective controlled study which was conducted during the period from January 2015 till December 2016.
Results: 2 groups of patients will be selected: group 1: 25 patients with diagnosed HCC due to HCV related liver disease. group 2: 25 patients with chronic liver disease due to hepatitis C virus (as a control group). Patients of group 1 underwent 25 sessions of TACE at the start of the study.
Conclusion: VEGF levels were significantly higher in HCC patients than in non-HCC patients. Pre-TACE serum VEGF levels are good predictors for response after TACE.
Recommendation: Larger scale multicenter studies are needed to apply VEGF assay on a larger number of HCC patients undergoing TACE. Applying VEGF assay in further follow up visits e.g 4 month after TACE to assess its clinical usefulness in assessment of tumor progression.